Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT ID: NCT02057770

Last Updated: 2018-10-12

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-02-28
• Study Completion Date: 2018-03-23

Brief Summary

The purpose of this research study is to look at overall health status and how acute myeloid leukemia (AML) responds to a stem cell transplant when followed with cyclophosphamide. Some participants enrolling in this study may receive a transplant from a sibling, some may receive a transplant from a matched unrelated donor, and some may receive what is called a haploidentical transplant. A haploidentical stem cell transplant is a type of transplant that occurs when a person who needs a transplant cannot find a donor who exactly matches their tissue type (either among family members or through a matched unrelated donor). When no matched donor is available, half-matched related (haploidentical) donors may be used. Haploidentical donors are first degree relatives such as siblings, children, or parents.

People who undergo a stem cell transplant can experience complications such as rejection of the stem cell transplant or severe graft-versus-host disease (GVHD). GVHD occurs when some of the cells from the donor attack the recipient's tissues, resulting in mild, moderate, or even life-threatening side effects to the recipient's skin, stomach, intestines, and liver. However, recent research has shown that receiving cyclophosphamide after stem cell transplant can improve the outcomes of the transplant, and that is the purpose of this study.

Conditions

Leukemia, Myeloid, Acute

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment (preparative regimen, transplant, cyclophosphamide)

BUSULFAN AND FLUDARABINE BASED PREPARATIVE REGIMEN: Patients receive busulfan IV over 3 hours on days -7 to -4, fludarabine phosphate IV over 30-60 minutes on days -6 to -2, and cyclophosphamide IV over 60 minutes on days -3 and -2.

OR

FLUDARABINE AND TBI BASED PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30-60 minutes on days -6 to -4 and undergo TBI twice daily on days -3 to 0.

AND

DONOR CELL INFUSION: Patients undergo HLA-matched sibling stem cell transplant, HLA-matched unrelated, or HLA-haploidentical transplant on day 0.

AND

POST-TRANSPLANT CYCLOPHOSPHAMIDE: Patients receive cyclophosphamide IV over 90 minutes on days 3 and 4.

Group Type: EXPERIMENTAL

busulfan

Intervention Type: DRUG

fludarabine phosphate

Intervention Type: DRUG

total-body irradiation (TBI)

Intervention Type: RADIATION

Stem cell transplant

Intervention Type: PROCEDURE

cyclophosphamide

Intervention Type: DRUG

CRS preventive regimen

The final \~15 people enrolled who will be recipients of haploidentical transplants will receive tocilizumab IV over 60 minutes 6-12 hours prior to the start of the donor cell infusion.

Group Type: EXPERIMENTAL

tocilizumab

Intervention Type: DRUG

Interventions

busulfan

Intervention Type: DRUG

fludarabine phosphate

Intervention Type: DRUG

total-body irradiation (TBI)

Intervention Type: RADIATION

Stem cell transplant

Intervention Type: PROCEDURE

cyclophosphamide

Intervention Type: DRUG

tocilizumab

Intervention Type: DRUG

Other Intervention Names

Myleran®; Fludara®; 2-Fluoro-ara-A Monophosphate; 2-Fluoro-ara AMP, FAMP; Cytoxan®; CPM; CTX; CYT; anti-IL-6 monoclonal antibody; Actemra

Eligibility Criteria

Inclusion Criteria

• AML without complete remission (CR/CRc/CRi) after at least 2 induction therapies OR
• AML that has relapsed within 6 months after obtaining a CR OR
• AML that has relapsed more than 6 months after obtaining a CR, and has treatment failure (TF) or progressive disease (PD) following at least 1 re-induction regimen OR
• AML that has relapsed post Allogeneic transplantation
• Active AML (bone marrow blasts ≥ 5% by morphology, staining, or flow) and/or presence of estramedullary disease
• Available HLA-haploidentical donor that meets the following criteria:

• Blood-related family member (sibling (full or half), offspring, or parent, cousin, niece or nephew, aunt or uncle, or grandparent)
• At least 18 years of age
• HLA-haploidentical donor/recipient match by at least low-resolution typing per institutional standards
• In the investigator's opinion, is in general good health, and medically able to tolerate leukapheresis required for harvesting HSC
• No active hepatitis
• Negative for HTLV and HIV
• Not pregnant

NOTE: there were HLA-matched sibling and HLA-matched unrelated donor cohorts, but those closed without completion of accrual with Amendment 11

• Karnofsky performance status ≥ 50 %
• Adequate organ function as defined below:

• Total bilirubin ≤ 2.5 mg/dl (unless the patient has a history of Gilbert's syndrome)
• AST(SGOT) and ALT(SGPT) ≤ 3.0 x IULN
• Creatinine ≤ 2.0 x IULN OR estimated creatinine clearance ≥ 30 mL/min/1.73 m2 by Cockcroft-Gault Formula
• Oxygen saturation ≥ 90% on room air
• LVEF ≥ 40%
• FEV1 and FVC ≥ 40% predicted, DLCOc ≥ 40% predicted. If DLCO is < 40%, patients will still be considered eligible if deemed safe after a pulmonary evaluation.
• At least 18 years of age at the time of study registration
• Able to understand and willing to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable)

Exclusion Criteria

• Circulating blast count ≥ 10,000/uL by morphology or flow cytometry (cytoreductive therapies including leukapheresis or hydroxyurea are allowed)
• Known HIV or Active hepatitis B or C infection
• Known hypersensitivity to one or more of the study agents
• Currently receiving or has received any investigational drugs within the 14 days prior to the first dose of study drug (Day -7)
• Currently receiving or has received any intensive chemotherapy within the 14 days prior to the first dose of study drug (Day -7) (hydrea or other non-intensive regimens such as decitabine may be used but must stop at least one day prior to the first dose of study drug)
• Pregnant and/or breastfeeding
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmias, or psychiatric illness/social situations that would limit compliance with study requirements.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Washington University School of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Todd Fehniger, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Washington University School of Medicine

Locations

Washington University School of Medicine

St Louis, Missouri, United States

Countries

United States

Related Links

http://www.siteman.wustl.edu

Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Other Identifiers

201401080

Identifier Type: -

Identifier Source: org_study_id